UnknownNot Applicable

Assessment of Artificial Intelligence for Treatment Decision Recommendation of Adult Skeletal Class III Patients

Egypt150 participantsStarted 2023-05-01

Plain-language summary

The study titled "Reliability Of Artificial Intelligence for Treatment Decision Recommendation of Adult Skeletal Class III Patients" aims to assess the accuracy and dependability of artificial intelligence (AI) in providing treatment decision recommendations for adult patients with skeletal Class III malocclusion. Skeletal Class III malocclusion is characterized by an underdeveloped upper jaw or an overdeveloped lower jaw, leading to facial and dental irregularities. The study focuses on evaluating whether AI-based recommendations can reliably guide orthodontic treatment planning for this specific patient group. This diagnostic test accuracy study involves collecting a diverse dataset of adult patients diagnosed with skeletal Class III malocclusion. AI algorithms will be trained on this dataset using various clinical and radiographic parameters to learn patterns and make treatment recommendations. The study will then compare the AI-generated treatment recommendations to those provided by experienced orthodontists. Key aspects of the study include: AI Reliability: The primary objective is to assess how consistently and accurately the AI system can recommend appropriate treatment decisions for adult skeletal Class III patients. Diagnostic Test Accuracy: The study will determine the sensitivity, specificity, positive predictive value, and negative predictive value of the AI-generated treatment recommendations. This analysis will highlight the AI's ability to correctly identify patients who require specific treatment interventions. Clinical Validity: Researchers will investigate whether the AI recommendations align with the decisions made by experienced orthodontists. This assessment is crucial to establish the AI system's clinical applicability. Potential Benefits: If the AI system proves reliable and accurate, it could offer a time-efficient and standardized method for treatment decision support, aiding orthodontists in providing personalized care to adult skeletal Class III patients. By conducting this study, researchers aim to contribute to the advancement of AI-assisted medical decision-making within the field of orthodontics. Successful outcomes would have the potential to revolutionize treatment planning processes, improve patient outcomes, and provide a valuable tool for orthodontists to make informed treatment decisions for adult skeletal Class III patients

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Skeletally mature patients with CVMI 6. * Skeletal class III patients * No congenital deformity, syndrome, or cleft. * No previous surgical intervention * No mandibular transverse functional shift. * Normal overjet, overbite after completion of treatment. * Patients with well finished occlusion. * Patients who have achieved adequate functional and aesthetic results at the end of their treatment. * Good quality initial and final lateral cephalometric radiographs. * No sex predilection. Exclusion Criteria: * Adolescents and skeletally immature patients. * Patients with pseudo class III. * Syndromic patients. * Patients with facial deformity at the naso-maxillary complex

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

sensitivity and specificity

Timeframe: 1 month

Trial details

NCT IDNCT06002373

SponsorCairo University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-01

Contact for this trial

Maha AM Swelam, PhD

00201123344551 maha.swelam@gmail.com

View on ClinicalTrials.gov More Skeletal Dysplasia trials